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Abstract
Radiotherapy is used to treat cancer patients by damaging DNA of tumor cells using ioniz-
ing radiation. Photons are the most widely used radiation type for therapy, having been put
into use soon after the first discovery of X-rays in 1895. However, there are emerging interests
and developments of other radiation modalities such as protons and carbon ions, owing to their
unique biological and physical characteristics that distinguish these modalities from photons. Cur-
rent attempts to determine an optimal radiation modality or an optimal combination of multiple
modalities are empirical and in the early stage of development. In this paper, we propose a math-
ematical framework to optimize full radiation dose distributions and fractionation schedules of
multiple radiation modalities, aiming to maximize the damage to the tumor while limiting the
damage to the normal tissue to the corresponding tolerance level. This formulation gives rise to
a non-convex, mixed integer program and we propose a bilevel optimization algorithm, to effi-
ciently solve it. The upper level problem is to optimize the fractionation schedule using the dose
distribution optimized in the lower level. We demonstrate the feasibility of our novel framework
and algorithms in a simple 2-dimensional phantom with two different radiation modalities, where
clinical intuition can be easily drawn. The results of our numerical simulations agree with the
clinical intuition, validating our approach and showing the promise of the framework for further
clinical investigation.
1 Introduction
The number of patients diagnosed with cancer is increasing every year, projecting over 1.9 million
new cancer cases in 2020 according to the Centers for Disease and Control and Prevention (CDC) [1].
More than half of all cancer patients go through radiotherapy in the course of their cancer treatment.
Radiotherapy utilizes ionizing radiation to kill cancer cells and is used as the primary treatment
modality for certain cases or as an (neo)adjuvant modality before or after other treatment modalities
such as surgery and chemotherapy. Although radiation kills cancer cells, it also damages normal tissue
that is on its path. Therefore, the goal of radiotherapy is to maximize the differential in the damages
between the tumor and normal tissue.
External beam radiation therapy (EBRT) is a non-invasive type of radiotherapy, where the radiation
generated by linear accelerators or cyclotrons is targeted at the tumor from outside the patient’s body.
Figure 1 (a) shows a linear accelerator that produces X-rays and electrons to treat the patient lying on
the table. There are currently multiple radiation types used in EBRT. The most widely used radiation
type is photons (X-rays) and the therapeutic effect of photons on the tumor and normal tissue is
well-established due to their long history of use. However, there are emerging interests in the EBRT
using heavy charged particles such as protons and carbon ions due to their unique dosimetric and
biological characteristics. For example, Figure 1 (b) shows the percent depth dose (PDD) of photons
(X-rays) and protons. Unlike photons, which deposit the maximum dose near the patient’s surface,
typically within 3 cm from the beam entrance for photons with the energy of less than 18 MV used
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Figure 1: (a) Elekta medical linear accelerator at the University of Washington Medical Center (b)
Percent depth dose comparison between X-rays and protons..
in clinical practice, protons deposit the maximum dose at the end of their range. Since the range of
protons is dependent on their energy, we can theoretically aim to deposit a large amount of dose in
the tumor, leaving the normal tissue behind it almost no dose by adjusting the energy of the particles.
This superior dosimetric effect of heavy charged particles compared to conventional photons can be
easily seen in the isodose distributions in Figure 2 for the patient with craniospinal irradiation. The
patient treated with protons on the top receives much less dose to the normal tissue outside the target
area (whole brain and spinal cord) compared to the patient on the bottom, where the patient is treated
with photons. It is particularly beneficial for pediatric patients whose secondary malignancy is a great
concern.
On the other hand, certain radiation types such as neutrons and carbon ions have superior biological
effects compared to photons. A relative biological effectiveness (RBE) is defined as the ratio of the
absorbed dose of a reference radiation type (often photons) and another radiation type, which kills
the same number of cells. For example, the RBE of neutrons is defined as DX/Dn, where DX and Dn
are the dose that kills the same number of cells using photons and neutrons respectively. Therefore, a
radiation type with a higher RBE kills more cells than photons given the same physical dose (absorbed
energy per unit mass). By definition, RBE is dependent on the radiation type, tissue type (what type
of cells is considered in computing RBE), and the environment condition such as the level of oxygen [2].
For example, fast neutrons used for radiotherapy have an RBE of 2-5 [3, 4] and it is particularly high
in a hypoxic condition such as in the tumor. It is noteworthy that radiation with a higher RBE implies
that it damages both tumor and normal tissue more than conventional photons but the differential is
not uniformly scaled throughout various tissue types. Therefore, there is an opportunity to exploit
the differential to maximize the therapeutic effect. The summary of radiation types currently used
in practice worldwide and their dosimetric and biological effect relative to conventional photons is
presented in Table 1.
Radiation Type Dosimetric effect Biological damage Cost [5]
Protons Superior Similar 3-4 times more
Neutrons Similar Superior Similar
Carbon ions Superior Superior 5-6 times more
Table 1: Comparison of various radiation types. All are relative to photon (X-ray) external beam
radiotherapy, which is currently the most widely used radiation type in practice.
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Figure 2: Craniospinal irradiation patient plans (Top) Isodose distributions with a single posterior-
anterior photon beam (Bottom) Isodose distributions with a single posterior-anterior proton beam.
Both plans are normalized to 3600 cGy at 100 %.
Due to the unique dosimetric and biological effect of each radiation type, and practical consid-
erations, there is no single modality that is superior to others in all aspects. Furthermore, it is not
obvious which radiation type is optimal for a specific patient. Current efforts to determine an optimal
radiation type or combination of radiation types are mostly empirical and largely depend on clinical
intuitions [6, 7, 8, 9]. More recently, there are some efforts to systematically optimize proton and
photon treatments combined. We previously studied a simplified scenario, where the dose from two
different radiation types is expressed in a scalar form, and proposed a mathematical framework to find
an optimal fractionation for each radiation modality [10] and its robust counter part in [11]. Unkelbach
et al. minimized the mean biologically effective dose (BED) of organs-at-risk while prescribing a fixed
BED to the tumor with a fixed fractionation for both protons and photons [12]. Gao et al. studied
the hybrid proton-photon inverse planning optimization in [13], where they also optimized the dose
distribution from both modalities using the fixed prescription dose to the tumor and fixed fractionation
schedules. Eikelder et al. studied the fluence map-fractionation schedule optimization of proton and
photon combined using a sparing factor [14]. The idea of a sparing factor in the fractionation schedule
optimization is explained in detail in [15] with a single modality case. In summary, the relative dose
of OAR in each voxel is fixed as a fraction of the tumor dose through a sparing factor. Eikelder et
al. took a heuristic approach to proton-photon modality fractionation optimization problem, where
the maximum feasible BED to the tumor was computed for all possible combinations of fractions for
each modality to find an optimal fractionation schedule. In particular, their approach separates the
fractionation schedule optimization from the fluence map optimization because the sparing factors are
not optimization variables.
The purpose of this study is to:
1. Set up a full-scale, rigorous mathematical framework to simultaneously optimize dose distribu-
tions and fractionations of two or more radiation modalities. In other words, the dose distribution
optimization and fractionation optimization of multiple modalities are integrated.
2. Develop an efficient optimization algorithm to find optimal fractionation and corresponding op-
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timal fluence maps (and resulting dose distributions) for each modality.
3. Test the feasibility and clinical relevance of the proposed framework on a small-scale phantom,
where clinical intuition can be used to validate the results of the numerical simulation.
1.1 Contribution
We develop a rigorous optimization approach for the radiation treatment planning problem using M
radiation modalities. We propose a novel, integrated framework that can simultaneously optimize dose
distributions and fractionations of multiple modalities in full, voxel-by-voxel scale. In other words, we
seek the solutions to the problem, which exploit the full flexibility of treatment parameters (i.e. number
of modalities, fluence maps, number of fractions).
Our work focuses on developing a non-convex optimization framework, where the biological effect
(BE) to the tumor is maximized while the normal tissue BE is kept under the tolerance level. The
optimization variables are the fluence maps of each modality (um,m = 1, · · · ,M) and its correspond-
ing number of fractions (Nm). We also develop a bilevel optimization algorithm to solve for optimal
{um}Mm=1 and {Nm}Mm=1. The lower level optimizes um using non-convex relaxation for a fixed frac-
tionation schedule. The upper level relaxes the integrality of Nm and solves the resulting continuous
optimization problem using a trust region algorithm, calling the lower level as a subroutine. We
demonstrate the feasibility of the proposed framework by applying it to a small-scale phantom case.
This paper is organized as follows: the problem formulation and optimization framework are pre-
sented in Section 2 followed by the optimization algorithms to solve the problem in Section 3. The
numerical simulations and their results are presented in Section 4. We conclude in Section 5 with some
remarks for the future work.
2 Problem Formulation
Let us consider optimizing the dose distributions using M modalities, where each modality m delivers
Nm fractions (m = 1, 2, · · · ,M). Biological effect (BE) based on the linear-quadratic (LQ) cell-survival
model is widely used in radiation oncology to characterize the effect of the physical dose (the energy
absorbed per unit mass) combined with the fractionation effect [2]. We use BE to compare the effect
of two different fractionation schedules on cell-killing since the same total (physical) dose could lead to
a different biological outcome depending on the fractionation schedule. For example, 10 Gy delivered
to the tumor in 1 fraction kills more tumor cells than 10 Gy delivered in 5 fractions. BE of delivering
one-dimensional dose dm to the tumor for Nm fractions for a single radiation modality m is given by
BE = αmNmd+ βmNmd
2 − τ(Nm), (1)
where αm and βm are radiation modality and tissue-specific radiobiological parameters in the LQ
model and τ(Nm) is a tumor proliferation term, only depends on the length of treatment.
The goal is to maximize the total tumor BE (sum of BEs across modalities) while keeping each of
the organ-at-risk (OAR) total BEs under tolerance, using M radiation modalities with Nm fractions
for each modality. In the multidimensional case, the radiobiological parameters of each radiation
modality αm and βm are vectors, and each dose distribution dm is the image of fluence map um under
the dose mapping. We use a linear dose mapping for the dose calculation, so that dm = Amum. OAR
constraint types included in this paper are mean dose constraints and maximum dose constraints, which
are common in practice for parallel1 and serial2 normal tissue types respectively. Another common
constraint type for OAR in practice is dose-volume (DV) constraints, which specify a critical volume
1The organ remains functional when part of it is damaged by radiation.
2If any part of an organ is damaged, the organ becomes no longer functional.
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of OAR that must receive less than a certain critical dose value. DV constraints can be easily handled
using a constraint generation method, where the initial optimization is done without DV constraints
and then the maximum constraints are applied to specific voxels in the subsequent optimization if DV
constraints are violated in the first optimization [16, 15, 17]. Since DV constraints can be handled by
maximum constraints with some modification in the algorithm, we do not include DV constraints for
the brevity of notations.
2.1 Notation
We use the following notation to describe the proposed model:
• M : total number of radiation modalities
• um: fluence map (beamlet intensities) for modality m
• Nm: number of fractions for modality m
• Tm: tumor dose coefficient matrix for modality m such that Tmum gives the dose distribution
delivered to the tumor using a fluence map um
• Tm(j): j-th row of matrix Tm
• Him: i-th OAR dose coefficient matrix for modality m
• Him(j): j-th row of matrix Him
• n: number of OARs
• l: number of voxels in the tumor
• J0: voxel index set for the tumor (so |J0| = l)
• Ji: voxel index set for the i-th OAR, i = 1, 2, · · · , n
• Imean: index set of OARs with mean-dose constraint
• Imax: index set of OARs with max-dose constraint
• αm, βm: vectors of the linear and quadratic radiobiological coefficients in the tumor BE for
modality m;αm, βm ∈ R|J0|++
• γim, δim: vectors of the linear and quadratic radiobiological coefficients in the i-th OAR BE for
modality m; γm, δm ∈ R|Ji|++
• αm(j), βm(j), γim(j), δim(j): j-th element of the corresponding vector
• Cimean: tolerance BE for the i-th OAR with a mean dose constraint
• Cimax: tolerance BE for the i-th OAR with a maximum dose constraint
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2.2 Optimization Framework
We now formulate the fully general multi-modality radiotherapy framework: M radiation modalities
with Nm fractions for the m-th modality. We denote tumor dose coefficient matrices which map
beamlet intensities um to the dose distribution for each modality by Tm, and OAR dose coefficient
matrices that map um to the dose distribution delivered to the i-th OAR by H
i
m. Our objective is to
maximize the total tumor BE, subject to the mean and max constraints on the OAR BEs:
(P0) max
{um, Nm}Mm=1
M∑
m=1
∑
j∈J0
Nmαm(j)(Tm(j)um) +Nmβm(j)(Tm(j)um)
2 − τ(Nm) (P0.1)
s.t.
M∑
m=1
∑
j∈Ji
Nmγ
i
m(j)(H
i
m(j)um) +Nmδ
i
m(j)(H
i
m(j)um)
2 ≤ Cimean, ∀i ∈ Imean, (P0.2)
max
j∈Ji
{
M∑
m=1
Nmγ
i
m(j)(H
i
m(j)um) +Nmδ
i
m(j)(H
i
m(j)um)
2
}
≤ Cimax, ∀i ∈ Imax, (P0.3)
1 ≤
M∑
m=1
Nm ≤ Nmax, (P0.4)
Nm ∈ Z≥0, m = 1, . . . ,M, (P0.5)
um  0, m = 1, . . . ,M (P0.6)
This problem is a non-convex mixed integer program, which is NP-hard in general. We tackle this
problem by devising a bilevel optimization algorithm, where in the upper level, we relax integrality
constraints and optimize the fractionation schedule over {Nm}Mm=1 using the optimal fluence map
{um}Mm=1 obtained from the lower level for a given fractionation schedule. The details of the algorithms
are presented in the following section.
3 Optimization Algorithms
In this section we develop a bilevel optimization algorithm to solve Problem (P0). The upper level
optimizing over fractionation schedules ({Nm}Mm=1) is detailed in Section 3.1 and the lower level ap-
proach (used as a subroutine in the upper level) to compute the optimal fluence map ({u∗m}Mm=1) for
fixed {Nm}Mm=1 is presented in Section 3.2.
3.1 Upper Level: Fractionation Schedule Optimization
In the upper level, we optimize the number of fractions of each modality. We first convert the max-
imization problem in Problem (P0) to a minimization problem. The tumor proliferation term in
Equations (1) and (P0.1) depends on the total treatment length, N . Assuming that there is no tumor
lagging time3, the tumor proliferation term with the total N fractions can be defined as
τ(N) =
ln 2(N − 1)
Td
, (3)
3time it takes for the tumor to start proliferation after the treatment starts
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where Td is the tumor doubling time
4 [2]. Using (3), we can rewrite (P0) as follows:
(P1) min
{um, Nm}Mm=1
M∑
m=1
Nm
{−αmTTium − (Tmum)Tdiag(βm)(Tmum)}+ l
(∑M
m=1Nm − 1
)
ln 2
Td
(P1.1)
s.t.
M∑
m=1
Nm
{
γim
T
Himum + (H
i
mum)
Tdiag(δim)(H
i
mum)
}
≤ Cimean, ∀i ∈ Imean, (P1.2)
max
j∈Ji
{
M∑
m=1
Nmγ
i
m(j)(H
i
m(j)um) +Nmδ
i
m(j)(H
i
m(j)um)
2
}
≤ Cimax, ∀i ∈ Imax, (P1.3)
1 ≤
M∑
m=1
Nm ≤ Nmax, (P1.4)
Nm ∈ Z≥0, m = 1, . . . ,M, (P1.5)
um  0, m = 1, . . . ,M (P1.6)
where l is the total number of voxels in the tumor. Let F ({um}Mm=1, {Nm}Mm=1) denote the objective
function in (P1.1). To solve the problem, we relax integrality constraints and solve the continuous
optimization problem.
(P2) min
N1, · · · , NM
V (N1, · · · , NM ) (P2.1)
s.t.
1 ≤
M∑
m=1
Nm ≤ Nmax, (P2.2)
Nm ≥ 0, m = 1, . . . ,M, (P2.3)
where V (N1, . . . , NM ) is the value function of {Nm}Mm=1 defined by
V (N1, . . . , NM ) := F ({u∗m(N1, . . . , NM )}Mm=1, N1, . . . , NM ) (6)
where each u∗m(N1, . . . , Nm) is the optimal fluence map solution for fixed fractionation (N1, . . . , Nm):
{u∗m(N1, . . . , NM )}Mm=1 = arg min
u
(P2(N1, . . . , NM )). (7)
Every evaluation of the value function V requires solving an optimization problem in the fluence
maps (see Equation (7)), and this is done using the lower level soluton approach discussed in Section
3.2. Problem (P2) has a nonlinear nonconvex objective with simple linear inequality constraints, and
we solve it using a trust region method [18] for constrained optimization as implemented in Python
package, SciPy [19]. The solution of (P2) is rounded to the nearest integers, N∗f in a post-processing
step. Once we have an integral N∗f , we also update fluence maps u
∗
f = arg minu(P1(N
∗
f )) to ensure
that the optimality and feasibility are enforced for the integer solutions. The upper level solution
approach is described in Algorithm 1. Since the problem is nonconvex, we repeat Algorithm 1 for
multiple initial guesses of {N (0)m } and the best solution is chosen as the final optimal solution.
4time it takes for the tumor to double in the number of cells
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Algorithm 1 {Nm} Fractionation Schedule Optimization
1: Input: u(0), N
(0)
1 , . . . , N
(0)
M
2: function ObjectiveFun(u,N1, . . . , NM )
3: return
∑M
i=1Ni(αi
TTiui − (Tiui)Tdiag(βi)(Tiui)) + ntx
(∑M
j=1Nj − 1
)
ln 2/Td.
4: function ValueFun(N1, . . . , NM ) . Define the value function to optimize
5: u∗N ←LowerLevelSolver(u(0), N1, . . . , NM )
6: return ObjectiveFun(u∗N , N1, . . . , NM )
7: N∗1 , . . . , N
∗
M ← TrustRegionConstr(ValueFun, N (0)1 , . . . , N (0)M ,
∑M
j=1Nj ≤ 25, {Nj ≥ 0}M1 )
8: u∗ ← LowerLevelSolver(u(0), [N∗1 ], . . . , [N∗M ])
9: Output: u∗, N∗1 , . . . , N
∗
M
3.2 Lower Level: Fluence Map Optimization for Fixed Fractionation
In this section, we describe the lower level solution required to compute (7) for a given fractionation
schedule. The tumor proliferation term is independent of um and does not affect the problem for fixed
Nm. Next, every maximum dose constraint in (P1.3) can be viewed as a mean dose constraint applied
to every single voxel of a given OAR, essentially treating each of those voxels as a mean-dose OAR in
its own right. The dose mapping matrices for those ”new OARs” are comprised of the corresponding
rows of the original OAR dose mapping matrices. Let us specify the dose mapping and BE coefficient
matrices in terms of these new OARs. First, noting that all the voxel index sets J1, . . . , Jn are disjoint,
define the index set of all OAR voxels with maximum dose constraints as follows:
I˜max = {i = (j, k)|k ∈ Imax, j ∈ Jk}. (8)
I˜max is the index set of our new ”mean-dose OARs”. Now, for any OAR i = (j, k) ∈ I˜max, define the
corresponding dose coefficient matrix for modality m as Hkm(j) (in fact, this would be a row-vector)
and arrange M dose coefficient matrices into a single block-diagonal generalized dose matrix Hi for
the OAR i. Stack the corresponding linear BE coefficients into vectors and include the fixed Nm to
obtain the following generalized linear BE coefficients:
Hi =

Hk1 (j)
Hk2 (j)
. . .
HkM (j)
 , γ˜i =

N1γ
k
1 (j)
N2γ
k
2 (j)
...
NMγ
k
M (j)
 . (9)
Similarly, for every OAR i ∈ Imean arrange the dose matrices of each modality into block-diagonal
generalized dose matrices and stack the linear BE coefficients into large generalized linear BE coefficient
vectors, do the same for the tumor dose matrices and BE coefficients getting:
Hi =

Hk1
Hk2
. . .
HkM
 , γ˜i =

N1γ
k
1
N2γ
k
2
...
NMγ
k
M
 , T =

T1
T2
. . .
TM
 , α˜ =

−N1α1
−N2α2
...
−NMαM
 . (10)
Rearranging the sums in equations (P0.1) and (P0.2) of the Problem (P0) and rewriting the max-dose
constraints (P0.3) in terms of the new one-voxel mean-dose-constrained OARs, we reformulate the
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Problem (P0) for fixed {Nm}Mm=1 as follows:
min
u
α˜T (Tu)− (Tu)TB(Tu)
s.t.
γ˜i
T
Hiu+ (Hiu)TDi(Hiu) ≤ Cimean, ∀i ∈ Imean,
γ˜i
T
Hiu+ (Hiu)TDi(Hiu) ≤ Cimax, ∀i ∈ I˜max,
u  0.
where
u =

u1
u2
...
uM
 , B =

N1diag(β1)
N2diag(β2)
. . .
NMdiag(βM )
 ,
and
Di =

N1diag(δ
i
1)
N2diag(δ
i
2)
. . .
NMdiag(δ
i
M )
 ∀i ∈ Imean,
Di =

N1δ
k
1 (j)
N2δ
k
2 (j)
. . .
NMδ
k
M (j)
 ∀i = (j, k) ∈ I˜max.
Here, diag(v) denotes the diagonal matrix formed from a vector v, and the matrix B is block-diagonal
with blocks Nmdiag(βm). Likewise, the matrices D
i for i ∈ Imean are block-diagonal with blocks
Nmdiag(δ
i
m). Finally, D
i for i ∈ I˜max corresponding to the one-voxel mean-dose-constrained OARs
are diagonal M ×M matrices. For brevity, we denote the quadratic form with the matrix B as
f(x) := xTBx.
We now restate the optimization formulation for the fixed {Nm}Mm=1:
(P3) min
u
α˜T (Tu)− f(Tu) (P3.1)
s.t.
γ˜i
T
Hiu+ (Hiu)TDi(Hiu) ≤ Cimean, ∀i ∈ Imean, (P3.2)
γ˜i
T
Hiu+ (Hiu)TDi(Hiu) ≤ Cimax, ∀i ∈ I˜max, (P3.3)
u  0. (P3.4)
3.2.1 Non-Convex Relaxation
The optimization problem (P3) is non-convex since we are minimizing a concave objective function
and it is difficult to solve directly. To attack this problem, we follow the ideas of [20] and introduce
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auxiliary variables, w0 and wi with i = 1, 2, · · · , n˜, which gives us a more tractable relaxed problem:
(P4) min
u,w0, {wi}n˜i=1
α˜Tw0 − f(w0) + 1
2η0
‖w0 − Tu‖2 +
n˜∑
i=1
1
2ηi
‖wi −Hiu‖2 (P4.1)
s.t.
γ˜Twi + w
T
i D
iwi ≤ Cimean, ∀i ∈ Imean, (P4.2)
γ˜Twi + w
T
i D
iwi ≤ Cimax, ∀i ∈ I˜max, (P4.3)
u  0. (P4.4)
where n˜ = |Imean| + |I˜max|. The norm penalties force w0 and wi to be close to Tu and Hiu. The
parameters η0 and ηi control the degree of closeness, and, as η0, η1, . . . , ηn˜ go to zero, we recover (P3)
from (P4). We develop an automatic approach to select these parameters in Section 3.2.2. By design,
the auxiliary variables wi always meet the original mean or maximum BE constraints for every OAR.
To solve (P4), we use block-coordinate descent and iteratively update u,w0, and wis. We now
describe each update in detail.
Update w0, wi
For fixed u, the problem we solve is given by
(P5) min
w0, {wi}n˜i=1
α˜Tw0 − f(w0) + 1
2η0
‖w0 − Tu‖2 +
n˜∑
i=1
1
2ηi
‖wi −Hiu‖2 (P5.1)
s.t.
γ˜Twi + w
T
i D
iwi ≤ Cimean, ∀i ∈ Imean, (P5.2)
γ˜Twi + w
T
i D
iwi ≤ Cimax, ∀i ∈ I˜max (P5.3)
This problem is decoupled in w0 and wis and is therefore equivalent to solving for w0 and wi separately.
For w0, dropping the constant terms, we have
min
w0
αTw0 − f(w0) + 1
2η0
‖w0 − Tu‖2, (15)
which is equivalent to
min
w0
−f(w0) + 1
2η0
‖w0 − (Tu− η0α˜)‖2. (16)
The solution of this minimization step for w0 can be written compactly as
w+0 = prox−η0f (Tu− η0α˜), (17)
where the proximal operator, or prox, is defined by
prox−η0f (y) = arg minx
{
−f(x) + 1
2η0
‖x− y‖2
}
. (18)
Equation (17) gives us the update w+0 for w0. The proximal operator always exists for closed convex
functions, but care must be taken in the nonconvex case, and in particular for the concave −f(x). By
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analyzing the problem, we find the range of values η0 for which the proximal operator is well-defined
(see Appendix A):
(prox−η0f (y))j =

∞, maxi(Bii − 12η0 ) > 0 & j = arg maxi(Bii − 12η0 )
0, maxi(Bii − 12η0 ) > 0 & j 6= arg maxi(Bii − 12η0 )
1
η0
yj/(−2Bjj + 1η0 ), maxi(Bii − 12η0 ) ≤ 0.
(19)
In order for prox−η0f to be well-defined, we must have maxi(Bii − 12η0 ) ≤ 0. This assumption forces
a lower limit on the penalty parameter, making sure problems (P3) and (P4) are close, and gives us a
starting point for the parameter selection process discussed in Section 3.2.2.
Next, we consider the optimization problem with respect to each wi keeping only those terms that
depend on wi. We have n˜ number of problems with the same structure:
(P6) min
wi
‖wi −Hiu‖2 (P6.1)
s.t.
γ˜Twi + w
T
i D
iwi ≤ Cimean/max, ∀i ∈ Imean/I˜max (P6.2)
The solution of this problem is the projection of Hiu onto the convex set Ωi = {wi : γ˜Twi +
wTi Dwi ≤ Cimean/max}. The solution method to find the projection,
projΩi(v) = arg minw∈Ωi ‖w − v‖2
is presented in Appendix B. Projection onto a closed convex set is a special case of the prox operator,
and is always well-defined and single-valued.
Update u
We now consider the subproblem for u for fixed w0 and wis. Dropping the constant terms, we have:
min
u0
1
2η0
‖w0 − Tu‖2 +
n˜∑
i=1
1
2ηi
‖wi −Hiu‖2 (21)
This is a non-negative least squares problem, which we solve using the Fast Non-Negative Least Squares
algorithm [21]. Algorithm 2 summarizes all updates of this block-coordinate descent algorithm. There
is only one block (with respect to w0) that does not necessarily have a unique minimum, and so
Algorithm 2 converges to a stationary point by the results of [22].
3.2.2 Automatic Parameter Selection
The relaxed problem (P4) uses multiple parameters: η0 and {ηi}n˜i=1. The auxiliary variable w0 cor-
responds to the tumor and wi corresponds to the i-th OAR with n˜ number of OARs in the problem
(including the introduced one-voxel maximum-dose-constraint OARs). Decreasing η0 enforces the op-
timality of the solution (i.e. maximizes the tumor BE) because Tu is forced to be closer to w0, while
decreasing ηi increases the penalty corresponding to the i-th OAR constraint and thus enforces the
feasibility of our solution making Hiu closer to wi. The existence of the proximal operator of the
function (−f) imposes an upper bound on η0:
η0 ≤ 1
2 maxiBii
. (22)
That is, the optimality penalty 12η0 should be big enough for the proximal operator to exist. This
gives us an initial value for the parameter choice procedure. Combining these ideas, we develop an
algorithm for the automatic selection of the parameters ηi:
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Algorithm 2 Fluence Map Optimization with Fixed Parameters and Fractions
1: Input: u(0), η0, η1, . . . , ηn˜, N1, . . . , NM
2: function LowerLevelFixedParams(u(0), η0, η1, . . . , ηn˜, N1, . . . , NM , Imean, I˜max)
3: Initialize: k = 0
4: α˜ :=
 −N1α1−N2α2...
−NMαM
 , B :=

N1diag(β1)
N2diag(β2)
. . .
NMdiag(βM )

5: for i = 1, . . . , n˜ do
6: γ˜i :=

N1γ
i
1
N2γ
i
2
...
NMγ
i
M
 , Di :=

N1diag(δi1)
N2diag(δi2)
. . .
NMdiag(δiM )

7: while not converged do
8: k ← k + 1
9: w
(k)
0 ← prox−η0f (Tu− η0α˜)
10: for i ∈ Imean do
11: Ωi = {wi : (γ˜i)Twi + wTi Diwi ≤ Cimean}
12: w
(k)
i ← projΩi(Hiu)
13: for i ∈ I˜max do
14: Ωi = {wi : (γ˜i)Twi + wTi Diwi ≤ Cimax}
15: w
(k)
i ← projΩi(Hiu)
16: u(k) ← arg minu0 α˜Tw(k)0 − f(w(k)0 ) + 12η0 ‖w
(k)
0 − Tu‖2 +
∑n˜
i=1
1
2ηi
‖w(k)i −Hiu‖2
17: u∗ ← u(k)
18: return u∗
19: Output: u∗
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1. Start η0 from the threshold in Equation (22). Initialize {ηi}n˜i=1 with the same value. Find the
solution u.
2. Check if any OAR constraints are violated by u found in Step 1.
3. Enforce feasibility: If there are any violated constraints, decrease ηi by setting η
+
i = ∆ηηi with
∆η < 1 and solve for new u
+. Repeat steps 2-3 until all OAR constraints are satisfied.
4. Enforce optimality, that is, decrease η0 by setting η
+
0 = ∆ηη0 and resolve for u
+ until u+ fails
to satisfy any constraint within the required tolerance for the OAR constraint.
Algorithm 3 summarizes the lower-level optimization solution algorithms including the automated
parameter selection with the fixed fractionation schedule N1, . . . , NM .
Algorithm 3 Lower Level Optimization with Automated Parameter Selection (fixed fractions)
1: Input: u(0), N1, . . . , NM
2: function LowerLevelSolver(u(0), N1, . . . , NM )
3: Initialize: η0 = η1 = · · · = 12 maxi Bii
4: u← LowerLevelFixedParams(u(0), η0, η1, . . . , ηn˜)
5: while there exists a violated constraint do
6: for i in the violated constraints index set do
7: ηi ← ηi ·∆η . Decrease ηi, enforce feasibility
8: u← LowerLevelFixedParams(u(0), η0, η1, . . . , ηn˜)
9: while there is no violated constraints do
10: η0 ← η0 ·∆η . Decrease η0, enforce optimality
11: u← LowerLevelFixedParams(u(0), η0, η1, . . . , ηn˜)
12: u∗ ← u
13: return u∗
14: Output: u∗
4 Numerical Simulations
We apply the proposed framework with two different radiation modalities, M1 and M2, to the 2D
phantom geometry shown in Figure 3. Since photons are currently the most widely used radiation
modality in practice, we investigate the impact of combining photons (M1) with a second modality
(M2), which has distinctive dosimetric characteristics as shown in Figure 2. In Section 4.1, we ex-
plain treatment planning and evaluation. Our framework is applicable to an arbitrary combination
of different modalities with unique dosimetric and biological characteristics, but to build intuition for
the proposal we investigate the impact of the difference between two modalities on the optimal BE
in simple stages. In Section 4.2, we consider the simple scenario of combining M1 with M2 that has
a dosimetric difference only, i.e. all radiobiological parameters between M1 and M2 are identical but
the dose mapping matrices are different, i.e., T1 6= T2 and Hi1 6= Hi2. In Section 4.3, we also add a
radiobiological difference between M1 and M2. We vary the tumor’s linear coefficients in the LQ model
for M2 (α2) and then vary the differential in the damage done by M2 between the tumor and OARs
(r). Finally, in Section 4.5, we present the performance of the optimal fractionation algorithm by com-
paring it to the true solution found using the brute-force technique, where all possible combinations
of (N1, N2) are individually used to find an optimal solution.
In all studies, we compute the initial guess, u0 in Algorithm 1, to give a uniform dose of 70 Gy
to the tumor without any OAR constraints, which is commonly used in practice for head-and-neck
tumors. The codes for our numerical simulations are available upon request.
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4.1 Phantom Geometry and Treatment Planning
The 2D phantom geometry in Figure 3 reflects a head-and-neck tumor surrounded by the spinal cord,
right parotid, and left parotid glands. The unspecified tissue 1 cm inside of the external contour
represents the skin of the patient. Adding a constraint for the unspecified tissue in the optimization
ensures that the dose outside the tumor and OAR does not exceed the tolerance level.
The dose mapping matrices for the first modality (T1, H
i
1) were computed using the Elekta linear
accelerator with 6 MV photons at the University of Washington. Radiation dose using M1 is assumed
to be delivered using seven equally spaced beams, i.e. gantry angles of 0◦, 51◦, 103◦, 153◦, 206◦,
257◦, and 309◦. The number of beamlets used is 195. The dose mapping matrices for the second
modality (T2, H
i
2) were computed using the proton beams with 250 MeV at the Seattle Cancer Care
Alliance Proton Therapy Center with 40 spot positions within the tumor. The radiation dose using
M2 is assumed to be delivered in one beam (gantry angle of 0
◦) as is often done in the proton therapy
practice. We assume that the maximum number of fractions allowed is 25 fractions (i.e. Nmax = 25).
Normal tissue tolerance BE and the radiobiological parameters used in computing BE were obtained
from published literature using photons and conventional fractionation schedules [23]. The α1/β1 ratio
is 10 Gy for the tumor with reference modality M1. The γ1/δ1 ratio is 2 Gy for the cord and unspecified
tissue, and 5 Gy for the right and left parotid glands with M1. The linear coefficients α1 and γ1 of the
LQ model are all assumed to be 0.35 Gy−1 for M1. The tolerance BE for all OARs used is summarized
in Table 2.
Constraint type δ1/γ1 Tolerance BE
Cord Maximum dose 2 Gy 35
Right Parotid Mean dose 5 Gy 12
Left Parotid Mean dose 5 Gy 12
Unspecified tissue Maximum dose 2 Gy 13.125
Table 2: Constraint type and tolerance biological effect for organs-at-risk (OAR) used in treatment
planning.
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We introduce a relative damage factor of r = δ2/α2 for M2 to capture the relative effect of M2 on
the tumor and OAR. When a modality has a larger biological effect on the tumor, it also damages
OAR more. However, the magnitude of the damage depends on tissue type, cell cycles, and other
conditions. Therefore, r is used to capture the differential in the damage between the tumor and OAR
by M2. As r increases, the damage to OAR is relatively greater than the damage to the tumor, making
M2 clinically undesirable. We used r ∈ {0.5, 1.0, 1.5}.
The evaluation of the proposed framework is performed using percentage improvement in BE
compared to BE obtained from two other methods with a single modality: (1) a conventional treatment
course and (2) a single modality treatment course with an optimal fractionation schedule.
Denote by Tconv the conventional treatment course with fixed 25 fractions using photons only, i.e.,
N1 = 25 fixed. Denote by Tsingle the treatment course with a single modality with photons and an
optimal number of fractions N†1 . Then the percentage improvement of the objective function value (=
BE) using the optimal double-modality treatment course T ∗ with (N∗1 , N
∗
2 ), where 1 ≤ N∗1 +N∗2 ≤ 25,
is given by
• Relative to a conventional course Tconv with N1 = 25 fixed
pObjconv =
BE using T ∗
BE using Tconv
× 100%.
• Relative to a single modality course Tsingle with the optimal N∗1
pObjsingle =
BE using T ∗
BE using Tsingle
× 100%.
4.2 Dosimetric Difference
In this section, we investigate the scenario where the only difference between M1 and M2 is the dose
mapping matrices for the tumor and OAR. All other radiobiological parameters are set to be the
same for the two modalities. The tumor doubling time, Td, is varied between 2 and 100 days, that
is, Td ∈ {2, 5, 20, 50, 100}. The percentage improvement in the optimal BE with T ∗ ranges between
105.7 % and 107.9 % compared to Tsingle, and between 107.7 % and 122.9 % compared to Tconv
depending on Td. The optimal number of fractions increases as Td increases, which agrees with clinical
intuition. Slowly growing tumors (i.e. larger Td) benefit from a long treatment course to reduce
the long-term normal tissue side effect since normal tissues have better capability to recover from
radiation damage than a tumor between fractions [2]. The additional improvement seen in pObjconv
compared to pObjsingle implies that the benefit of using T
∗ comes from both using optimal fractionation
schedule and multiple modalities. However, for a tumor with a large Td, there is no benefit of using
two modalities compared to a single modality with an optimal fractionation schedule. The complete
results are shown in Table 3.
4.3 Radiobiological Difference
In this section we present the results whenM2 has a radiobiological difference fromM1 in addition to the
dosimetric difference. First, we increase the linear coefficients in the LQ model, which means that M2
kills more cells thanM1. We used α2 ∈ {0.35, 0.55, 0.75} with r fixed at 1. The percentage improvement
in BE with T ∗ ranges between 106.6 % and 107.2% compared to the single modality course with optimal
fractionation Tsingle and between 109.6 % and 110.2 % compared to the conventional treatment course
Tconv with 25 fractions. There is no significant difference in the results using different α2 values, and
therefore the benefit of using M2 is not clear. This is likely because killing more cells applies to both
tumor and OAR. The complete results are shown in Table 4.
We next varied the relative damage factor r, that is the differential in the damage between the
tumor and OAR by M2. We used r ∈ {0.5, 1.0, 1.5}. When r = 1, the tumor’s linear coefficient in
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Td Dual modality Single modality
(days) optimal (N∗1 , N
∗
2 ) optimal (N
†
1 ) pObjsingle (%) pObjconv (%)
2 (2, 2) 2 105.7 122.9
5 (6, 6) 6 106.8 110.0
10 (13, 12) 13 107.9 108.2
50 (12, 12) 25 107.8 107.8
100 (12, 12) 25 107.8 107.8
Table 3: Optimal BE improvement with various tumor doubling time. Parameters are fixed at α2 =
0.35 Gy−1, r = 1.0
α2 Dual modality Single modality
(Gy−1) optimal (N∗1 , N
∗
2 ) optimal (N
†
1 ) pObjsingle (%) pObjconv (%)
0.35 (6, 6) 6 106.8 110.0
0.55 (10, 10) 8 106.6 109.6
0.75 (8, 7) 8 107.2 110.2
Table 4: Optimal BE improvement with various α2: parameters are fixed at r = 1, Td = 5 days.
the LQ model is the same as the OAR’s linear coefficient, i.e. α2 = δ2. A smaller r < 1 implies
that M2 damages the tumor more than OAR (α2 < δ2) and r > 1 implies the reverse relation. The
percentage improvement in BE with T ∗ ranges between 102.2 % and 125.7% compared to the single
modality course with optimal fractionation Tsingle and between 105.1 % and 129.4 % compared to the
conventional treatment course Tconv with 25 fractions fixed. The results are shown in Table 5. As r
decreases, the benefit of using a combination of M1 and M2 increases since M2 damages the tumor
more than OAR. This agrees with clinical intuition.
4.4 Uncertainty of M2
A modality with superior dosimetric or radiobiological characteristics often comes with a larger degree
of uncertainty. For example, protons deposit almost no dose beyond the Bragg peak but the uncertainty
in the location of the Bragg peak makes them less desirable since depositing a large dose at a position
slightly off target may result in an unacceptable dose to the tumor. Therefore, in practice, one strategy
to mitigate uncertainty is to ensure that a larger area around the tumor receives adequate dose by
adding an extra margin around the clinical target volume. Delivering a larger dose in a bigger target
volume often increases the dose to OAR, which is disadvantageous. To investigate the effect of this
extra margin used for M2 in our formulation, with hard constraints on OAR BEs, we add an extra
margin to the tumor for M2, compute the average BE per tumor voxel, and use it as an evaluation
criteria. The average BE per tumor voxel for M1 is computed without the extra margin, and therefore
we expect M1 to contribute a larger BE to the total tumor BE compared to the scenario, where the
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r Dual modality Single modality
optimal (N∗1 , N
∗
2 ) optimal (N
∗
1 ) pObjsingle (%) pObjconv (%)
0.5 (2, 19) 5 125.4 129.0
1.0 (6, 6) 6 106.8 110.0
1.5 (4, 4) 8 102.2 105.1
Table 5: Optimal BE improvement with various r: parameters are fixed at Td = 5 days and α2 =
0.35/Gy−1.
extra margin is not used for M2. The results of using the average tumor BE per voxel to compute
the pObjsingle and pObjconv reflect this clinical intuition and the optimal BE improvement of using
multi-modality is less than what was achieved in Section 4.3. The results are shown in Tables 6-8.
Td Dual modality Single modality
(days) optimal (N∗1 , N
∗
2 ) optimal (N
†
1 ) pObjsingle (%) pObjconv (%)
2 (1, 1) 2 102.5 119.2
5 (3, 4) 3 103.1 105.7
10 (12, 13) 12 102.9 103.2
50 (10, 14) 25 103.1 103.1
100 (11, 14) 25 103.4 103.4
Table 6: Optimal BE improvement for a range of tumor doubling times when an extra margin to the
tumor is used for M2. Parameters are fixed at α2 = 0.35 Gy
−1, r = 1.0
α2 Dual modality Single modality
(Gy−1) optimal (N∗1 , N
∗
2 ) optimal (N
†
1 ) pObjsingle (%) pObjconv (%)
0.35 (3, 4) 3 103.2 105.7
0.55 (6, 8) 6 102.3 105.4
0.75 (4, 5) 4 103.2 106.0
Table 7: Optimal BE improvement with various α2 when an extra margin to the tumor is used for
M2: parameters are fixed at r = 1, Td = 5 days.
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r Dual modality Single modality
optimal (N∗1 , N
∗
2 ) optimal (N
∗
1 ) pObjsingle (%) pObjconv (%)
0.8 (7, 11) 6 104.7 107.9
1 (3, 4) 3 103.2 105.7
1.2 (3, 3) 3 102.0 104.7
Table 8: Optimal BE improvement with various r when an extra margin to the tumor is used for M2:
parameters are fixed at Td = 5 days and α2 = 0.35/Gy
−1.
4.5 Optimal Fractionation
In this section, we demonstrate the performance of our approach for the fractionation schedule opti-
mization. We compute the “ground truth” using the brute-force technique, where (P3) is solved for all
possible integer (N1, N2) combinations with the constraint 1 ≤ N1+N2 ≤ Nmax (that is, we sample the
value function V (N1, N2) for all the points of the integer grid 1 ≤ N1 +N2 ≤ Nmax). Figure 4 shows
the value function V (N1, N2) defined in (6) in 3D (left) and the level sets of V (N1, N2) (right) obtained
from the brute-force technique. The iterates (N1, N2) of Algorithm 1 starting from the following four
different initial guesses are shown as colored dots on Figure 4 (the colors correspond to the different
initial points):
1. (N01 , N
0
2 ) = (1, Nmax − 1)
2. (N01 , N
0
2 ) = (Nmax − 1, 1)
3. (N01 , N
0
2 ) = (bNmax/2c, dNmax/2e)
4. (N01 , N
0
2 ) = (1, 1)
As shown in Figure 4, the output of Algorithm 1 is dependent on the initial guess, however, simple
initial guesses as implemented in our algorithm may be sufficient to find a clinically relevant optimal
solution. In our experiments, the above 4 initial guesses and 8 iterations of the upper level Algorithm
1 were sufficient to identify solutions close to the optimal.
5 Conclusion
We have developed a novel framework for radiation treatment planning with two or more radiation
modalities. The principle idea is to maximize the biological effect using the multiple modalities by
exploiting their unique dosimetric and biological characteristics captured through the dose mapping
matrices and radiobiological parameters in the LQ dose-response model. Our framework allows Nm = 0
as long as the sum of fractions of all modalities is equal to or greater than 1 fraction, and therefore
it will correctly identify an optimal combination even when a single modality is optimal. The pro-
posed framework ultimately offers an opportunity for an optimal multi-modality treatment planning
paradigm. The feasibility of the proposed method was demonstrated using a simple phantom case and
two modalities with varying only one parameter at a time such that clinical intuition can be applied.
The agreement of the outcome with clinical intuition validates the potential use of our algorithm in
more clinically relevant, complicated scenarios, where the clinical intuition is not readily available.
The challenge of this approach is the dependence of optimal solutions on the radiobiological pa-
rameters, which is indeed a challenge of biological treatment planning in general. Active research
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Figure 4: The surface (left) represents V (N1, N2) computed by brute force. The dots represent iterates
starting from four different initial guesses.
on advanced imaging could relieve some of the concerns in estimating these parameters [24, 25]. A
novel algorithm we proposed to optimize the fractionation schedule with multiple modalities can be
easily adapted for a single modality case. A good choice of the initial guess is prudent for the optimal
fractionation schedule algorithm to converge to an optimal solution. Applications of our algorithm to
actual patient cases to evaluate the clinical significance and learning a good initial guess in the optimal
fractionation schedule algorithm from a large patient database are left for future work.
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Appendices
A Proximal Operator Calculation
prox−η0f (y) = arg minx
{
−f(x) + 1
2η0
‖x− y‖2
}
. (23)
Equation (17) gives us an update w+0 for w0. We note that the proximal operator is defined for
convex functions whereas our −f(x) is concave. Therefore, the minimization problem in (23) may
be unbounded. We will find the proximal operator by definition, that is, we will directly solve the
minimization problem (23). Recall that B is diagonal.
min
x
−xTBx+ 1
2η0
‖x− y‖2 (24)
⇔ min
x
−xTBx+ 1
2η0
xTx− 1
η0
〈y, x〉 (25)
⇔ min
x
−
∑
i
Biix
2
i +
1
2η0
∑
i
x2i −
1
η0
∑
i
yixi. (26)
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Finally, it is equivalent to
min
x
−
∑
i
(Bii − 1
2η0
)x2i −
1
η0
∑
i
yixi. (27)
Consider possible cases:
• If ∃i : (Bii − 12η0 ) > 0, then take x : xj = 0 ∀j 6= i, xi → ∞, the objective is unbounded below
since the quadratic term dominates over the linear term.
• If maxi(Bii− 12η0 ) ≤ 0, then we have a convex objective and therefore we can set derivative equal
to zero to find the optimum. We have:
−2Bx+ 1
2η0
2(y − x)(−1) = 0⇒ (−2B + 1
η0
I)x =
1
η0
y.
Thus,
(prox−η0f (y))j =

∞, maxi(Bii − 12η0 ) > 0 & j = arg maxi(Bii − 12η0 )
0, maxi(Bii − 12η0 ) > 0 & j 6= arg maxi(Bii − 12η0 )
1
η0
yj/(−2Bjj + 1η0 ), maxi(Bii − 12η0 ) ≤ 0.
B Projection Calculation
To find the projection, let us reformulate the problem as follows:
minw ‖w − v‖2
s.t. γ1w1 + γ2w2 + · · ·+ γnwn +D1w21 +D2w22 + · · ·+Dnw2n ≤ Cmean/max
where Di stands for the i-th diagonal element of D. Now, let us complete the square:
γ1w1 + γ2w2 + · · ·+ γnwn +D1w21 +D2w22 + · · ·+Dnw2n ≤ Cmean/max ⇔
( γ1
2
√
D1
)2 + 2(
√
D1w1)(
γ1
2
√
D1
) + (
√
D1w1)
2 + · · · ≤ Cmean/max + ( γ12√D1 )
2 + · · · ⇔∑
i(
γi
2
√
Di
+
√
Diwi)
2 ≤ Cmean/max +
∑
i(
γi
2
√
Di
)2.
Now, denote
K = Cmean/max +
∑
i(
γi
2
√
Di
)2, zi =
γi
2
√
Di
+
√
Diwi, then
wi =
1√
Di
(zi − γi2√Di ).
We finally get:
minz
∑
i(
1√
Di
zi − γi2Di − vi)2
s.t. ‖z‖2 ≤ K
Take the substitution Dˆ = diag( 1√
D1
, 1√
D2
, . . . , 1√
Dn
), li =
γi
2Di
+ vi and consider the following (using
KKT):
min
z
1
2
‖Dˆz − l‖22 + λ(‖z‖2 −K)
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In fact, we have:
L(z, λ) = ‖Dˆz − l‖22 + λ(‖z‖2 −K)
KKT:
∇L(z, λ) = DˆT (Dˆz − l) + 2λz = 0
λ(zT z −K) = 0
zT z ≤ K
λ ≤ 0
From the first condition, we have
z∗ = (DˆT Dˆ + λI)−1DˆT l.
If λ = 0, then we check the z∗ = (DˆT Dˆ)−1DˆT l to satisfy z∗T z∗ ≤ K. Otherwise, we look for the root
λ∗ of
‖(DˆT Dˆ + λI)−1DˆT l‖22 = K,
which we can find numerically by a root-finder routine. Then the projection is given by:
z∗ = (DˆT Dˆ + λ∗I)−1DˆT l.
Going back to the original variables,
wi =
1√
Di
(z∗i −
γi
2
√
Di
).
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